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mTORC1 activation in podocytes, and prevention of podocyte morphological changes by rapamycin treatment in db/db mice. (A) Foot process 
effacement in db/db mice is blocked by rapamycin (rapa). Glomeruli from mice at 25 weeks of age with the indicated genotypes were examined 
by TEM. Foot process width at the level of slit diaphragm was measured (100 foot processes/glomerulus, 4 glomeruli/mouse, 3 male mice/group); 
*P < 0.001 versus other groups, mean ± SEM. Rapamycin treatment (1 mg/kg, i.p. injection, 3 times/week) was performed from 8 to 25 weeks of age. 
Pod, podocyte. (B) mTORC1 activity is enhanced in the podocytes of diabetic animals. Double staining with anti–phospho-S6 and anti-WT1 antibodies 
was performed on frozen sections from mice of the indicated genotypes at 12 weeks of age. The arrows indicate enhanced phospho-S6 signal in 
the cytoplasm of db/db podocytes. Quantification of glomerular phospho-S6 (green) pixel density divided by glomerular area is shown. Data are 
expressed as fold induction (4 images per mouse, 3 male mice/group); *P < 0.001, mean ± SEM. Original magnification, ×13,500 (A); ×400 (B).
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Characterization of PcKOTsc1 mice. (A) Enhanced S6 phosphoryla-
tion, podocyte hypertrophy, and mesangial expansion in PcKOTsc1 
glomeruli. Renal tissues from 4-week-old mice of the indicated geno-
types were stained with phospho-S6, WT1, H&E, and PAS as indi-
cated. Representative glomeruli from wild-type, PcKOTsc1 (KO), and 
rapamycin-treated PcKOTsc1 (KO+rapa) are shown. Rapamycin treat-
ment (1 mg/kg, i.p., 3 times/wk) was performed from 2 to 4 weeks of 
age. (B) S6 but not Akt phosphorylation was enhanced in PcKOTsc1 
glomeruli. Levels of phospho-S6, S6, phospho-Akt (Ser473), and Akt 
in glomeruli from mice of the indicated genotypes were determined 
by Western blot. The levels of phosphorylation of each protein were 
quantified. Data are expressed as fold increase in the ratio of phospho-
protein to total protein. *P < 0.001 versus other groups; mean ± SEM, 
n = 3. (C) Enhanced matrix protein mRNAs in PcKOTsc1 glomeruli. 
The expression levels of fibronectin (FN) and type IV collagen (COL4) 
mRNAs in the indicated mouse glomeruli were determined by quan-
titative RT-PCR. Data were normalized to Hprt1. *P < 0.001 versus 
other groups; mean ± SEM, n = 7. (D) Enhanced deposition of the 
matrix proteins in PcKOTsc1 glomeruli. Representative glomerular 
images of staining for fibronectin and type IV collagen in the indicated 
animals are shown. The ratio of positive staining area to glomerular 
area in the indicated animals was determined (10 glomeruli/mouse, 
3 mice/group). *P < 0.001 versus other groups, mean ± SEM. Original 
magnification, ×400 (A and D).
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Figure 3
PcKOTsc1 mice show proteinuria and podocyte loss. (A) Rapamycin treatment prevents proteinuria in PcKOTsc1 mice. Scheme of admin-
istration of rapamycin is shown above. Urine (1 μl ) from mice of the indicated genotypes was subjected to SDS-PAGE with Coomassie blue 
staining (n = 6 each group). veh, vehicle. Asterisk indicates a leak of sample from lane 6. (B) Urinary albumin/creatinine ratio is shown. Urinary 
albumin and creatinine concentrations in 4-week-old mice were determined by ELISA. *P < 0.001 versus other groups, mean ± SEM, n = 6. Note 
logarithmic scale for the y axis. Rapamycin treatment was performed from 2 weeks of age as indicated in Figure 2A. (C) TEM analyses reveal 
abnormal foot process and GBM in PcKOTsc1 and wild-type mice. Representative TEM images of the indicated animals (3 mice/group) from 
4 and 8 weeks of age are shown. Rapamycin treatment was as in Figure 2A. Original magnification, ×13,500 (top row), ×7,900 (bottom row). Scale 
bars: 1 μm. (D) Scanning EM analyses show abnormal podocyte in PcKOTsc1 mice, which was prevented by rapamycin treatment. Rapamycin 
treatment was as in Figure 2A. Original magnification, ×2,000. Scale bars: 5 μm (top row); 1.25 μm (bottom row). (E) Podocyte loss in PcKOTsc1 
mice. The ratio (the number of WT1-positive cells/glomerular tuft area [μm2]) was determined in 15~30 glomeruli from the indicated animals. 
*P < 0.001 versus wild-type and/or KO with rapamycin treatment, mean ± SEM, n = 3–5 mice.
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Figure 4
Rapamycin reverses estab-
lished phenotypes in PcKOTsc1 
mice. (A and B) Rapamycin 
treatment ameliorated the 
established proteinuria in 
PcKOTsc1 mice. Proteinuria-
positive 4-week-old PcKOTsc1 
mice (n = 9) were treated with 
rapamycin for 2 and 6 weeks. 
The levels of urinary protein 
from 9 mice were tested at the 
indicated time points and visu-
alized by Coomassie staining 
(n = 9) (A), and the ratio of 
albumin to creatinine concen-
tration is shown (B). *P < 0.001 
versus other groups, mean ± 
SEM, n = 9; note logarithmic 
scale for y axis. The ratios for 
4- and 10-week-old wild-type 
mice are also shown. (C) H&E 
staining of renal tissue from 
4-week-old untreated and 
10-week-old treated PcKOTsc1 
mice (rapamycin treatment for 
6 weeks). Eosin-positive area 
in glomerulus was measured 
in 30 glomeruli from 4-week-
old wild-type and PcKOTsc1 
mice as well as 10-week-
old treated PcKOTsc1 mice. 
*P < 0.001 versus other 
groups, no statistical signifi-
cance between WT 4 weeks 
and KO with rapamycin 10 
weeks, mean ± SEM, n = 3~5. 
(D) TEM analyses of 10-week-
old PcKOTsc1 mice (rapamy-
cin treatment for 6 weeks). 
Foot process width at the level 
of slit diaphragm was mea-
sured (20~50 foot processes/
glomerulus, 3 glomeruli/mouse, 
3 mice/group). *P < 0.001 ver-
sus other groups, mean ± SEM. 
(E) Scanning EM analyses of 
6-week-old PcKOTsc1 mice 
(rapamycin treatment for 2 
weeks). Representative glom-
erulus from 2 different rapamy-
cin-treated PcKOTsc1 mice is 
shown. Original magnification, 
×400 (C), ×7,900 (D), ×2,000 
(E). Scale bars: 10 μm (top 
row); 2.5 μm (bottom row).
Downloaded from http://www.jci.org on November 8, 2017.   https://doi.org/10.1172/JCI44771
research article




















mTORC1 activation in podocytes causes proteinuria and mesangial expansion in adult mice. (A) Rapamycin prevents death in PcKOTsc1 mice. 
Mice were treated with rapamycin as indicated. Survival curve of the indicated animals is shown. Wild-type, n = 50; heterozygous (Het), n = 50; 
KO, n = 50; KO with rapamycin treatment (off-on), n = 15; KO with rapamycin treatment (off-on-off), n = 10; KO C57BL/6 (B6) background, 
n = 30. (B) mTORC1 activation in podocytes causes proteinuria and mesangial expansion in adult mice. Withdrawal of rapamycin treatment 
in adult PcKOTsc1 mice led to rapid onset of proteinuria and glomerulopathy. Scheme of administration of rapamycin is shown at top. Urinary 
albumin concentrations of the indicated animals were determined (WT 4 wk; KO 15 wk [rapamycin treatment from 2 to 15 weeks]; KO 16 wk, 
19 wk, and 21 wk [off-on-off; 1 wk, 4 wk, and 6 wk after withdrawal of rampamycin treatment]). *P < 0.001 versus WT and KO 15 wk, mean ± SD, 
n = 6. (C) Withdrawal of rapamycin treatment in adult PcKOTsc1 mice led to mesangial expansion. Scheme of administration of rapamycin is 
shown at top. H&E and PAS staining of the representative glomeruli are shown. PAS-positive area in glomerulus was measured in 30 glomeruli 
from the indicated animals. *P < 0.001 versus other groups, n = 4. Original magnification, ×400.
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mTORC1 activation converts podocytes to a fibroblastic phenotype and 







Hyperactivation of mTORC1 leads to mislocalization of slit diaphragm proteins. (A) Nephrin expression at interpodocyte filtration slit area is 
diminished in PcKOTsc1 mice. Representative electron micrographs of immunogold nephrin staining in 3-week-old mice are shown. Number 
of immunogold particles for nephrin at the slit diaphragm was measured in 290 slit diaphragms from 2 wild-type and 170 slit diaphragms from 
2 PcKOTsc1 mice. *P < 0.001 versus wild-type, mean ± SEM. (B) Nephrin and actin expression in the indicated glomeruli were determined by 
Western blotting. Levels of nephrin expression in the indicated genotypes were quantified (nephrin/actin). Data are expressed as fold increase. 
P = 0.67, mean ± SEM, n = 3. (C) Nephrin is mislocalized in PcKOTsc1 podocytes. Confocal microscopic analyses of nephrin and synaptopodin 
expression in the indicated animals (3 weeks old) are shown. Rapamycin treatment was performed for 1 week. Areas indicated by squares in the 
Merge column are shown at higher magnification in the right two columns. Original magnification, ×13,500 (A), ×400 (C).
Downloaded from http://www.jci.org on November 8, 2017.   https://doi.org/10.1172/JCI44771
research article
















Mislocalization of nephrin by abnormal mTORC1 activation and dia-
betes. (A) Membrane localization of nephrin is disrupted by Rheb. 
Exogenous nephrin expression pattern was analyzed by confocal 
microscopy. Human nephrin (Myc-Nephrin) was expressed with or 
without Rheb (HA-Rheb) in COS7 cells. Nephrin and Rheb expres-
sion was determined by rabbit polyclonal nephrin and mouse mono-
clonal HA antibodies, respectively. The arrowheads indicate mem-
brane expression of nephrin. Rapamycin (20 nM) treatment was for 
12 hours. (B) Rapamycin treatment restores membrane localization of 
nephrin in db/db mice. The pattern of nephrin expression of the indi-
cated animals (25 weeks of age) was monitored by confocal micros-
copy. Rapamycin treatment was performed from 8 to 25 weeks. The 
arrowheads indicate the accumulation of nephrin in cytoplasm. (C) 
Membrane localization of nephrin was reduced in human type 2 DN. 
Nephrin staining showed a granular pattern expression in cytoplasm 
with reduced membrane expression (NOR, normal subject; DN p1, 
DN patient 1). Original magnification, ×600 (A), ×400 (B, and C).
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Hyperactivation of mTORC1 induces ER stress and EMT-like pheno-
type in podocytes. (A) EMT-like phenotypic changes were induced in 
PcTSC1KO podocytes. Double staining with desmin and WT1 antibod-
ies was performed in renal tissues from the indicated animals and ana-
lyzed by confocal microscopy (top row). Arrowheads indicate desmin 
expression in the podocytes. Rapamycin treatment was performed for 
a week. ZO-1 expression was analyzed by confocal microscopy (bot-
tom row). Arrowheads indicate the liner expression pattern of ZO-1. 
(B) Detection of nephrin and podocin mRNA in PcTSC1KO urinary 
sediments. Twenty-four-hour urine samples were collected from the 
indicated animals. RT-PCR was performed using purified mRNA from 
the sediments. Glomerular mRNA was used as a positive control (p). 
(C) Accumulation of GRP78 in PcKOTsc1 podocytes (3 weeks of age). 
Double staining using anti-GRP78 and anti-synaptopodin antibodies in 
the indicated glomeruli is shown. Rapamycin treatment was performed 
for 1 week. (D) PBA treatment protects podocyte loss in PcKOTsc1 
mice. Staining with GRP78 plus synaptopodin, nephrin, H&E, and WT1 
is shown in the indicated animals (8 weeks of age). PBA treatment 
(400 mg/kg/d, i.p.) was performed for 6 weeks. (E) Podocyte number in 
the indicated glomerular sections from 8-week-old animals was mea-
sured. The ratio (number of WT1-positive cells/glomerular tuft area 
[μm2]) was determined in 15~30 glomeruli from the indicated animals 
as in Figure 3E. *P < 0.001 versus other groups, mean ± SEM, n = 4~8. 
(F) Urinary albumin concentrations were measured in the indicated 
animals. *P < 0.001 versus other groups; no statistical significance 
was observed between KO and KO with PBA treatment; mean ± SEM, 
n = 4~8. Original magnification, ×400 (A, C, and D).
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Figure 9
Podocyte-specific Raptor-heterozygous mice 
show resistance to the development of DN. (A) 
Podocyte-specific Raptor-heterozygous db/db 
mice (DM Raptor+/–) develop diabetes to the same 
extent as control db/db mice. Blood glucose lev-
els in the indicated animals are shown. *P < 0.001 
versus DM and DM Raptor+/–; no statistical signifi-
cance was observed between DM and DM Rap-
tor+/–; mean ± SEM, n = 6~8. (B) Twenty-four-hour 
urine volume of the indicated animals. Data are 
expressed as an average of the amount of urine for 
3 days. *P < 0.001 versus DM and DM Raptor+/–; 
no statistical significance was observed between 
DM and DM Raptor+/–; mean ± SEM, n = 6~8. (C) 
DM Raptor+/– mice show resistance to the develop-
ment of mesangial expansion. Representative H&E 
and PAS staining of the mice at 40 weeks of age 
is shown. (D) PAS-positive mesangial area was 
quantified using ImageJ software. PAS staining 
was performed in the indicated renal tissues, and 
PAS-positive mesangial area of 10–20 glomeruli 
cut at the vascular pole were measured. *P < 0.001 
versus other groups, mean ± SEM, n = 6~8. (E) 
DM Raptor+/– mice developed glomerular hypertro-
phy. Glomerular area was quantified as described 
in D. *P < 0.001 versus other groups; no statistical 
significance was observed between DM and DM 
Raptor+/–; mean ± SEM, n = 6~8. (F) Decreased 
RAPTOR dosage prevents nephrin mislocaliza-
tion in DM mice. Confocal microscopic analyses of 
nephrin and synaptopodin expression in the indi-
cated animals (40 weeks old) are shown. (G) DM 
Raptor+/– mice show resistance to proteinuria. Uri-
nary albumin and creatinine concentrations were 
measured in 24-hour urine samples from the indi-
cated animals. Albumin/creatinine ratio is shown. 
*P < 0.01 versus DM and control, mean ± SEM, 
n = 6~8. Original magnification, ×400 (C and F).
Downloaded from http://www.jci.org on November 8, 2017.   https://doi.org/10.1172/JCI44771
research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 121      Number 6      June 2011  2195


























































































































  8. Susztak K,  Raff  AC,  Schiffer M,  Bottinger  EP. 
Glucose-induced  reactive  oxygen  species  cause 
apoptosis of podocytes and podocyte depletion 
at  the  onset  of  diabetic  nephropathy. Diabetes. 
2006;55(1):225–233.
  9. Li JJ, et al. Podocyte biology in diabetic nephropa-
Downloaded from http://www.jci.org on November 8, 2017.   https://doi.org/10.1172/JCI44771
research article





















  17. Crino  PB,  Nathanson  KL,  Henske  EP.  The 

















































































in mice. J Am Soc Nephrol. 2006;17(11):3093–3104.
  39. Reidy K, Susztak K. Epithelial-mesenchymal transi-
tion and podocyte loss in diabetic kidney disease. 

























one. J Am Soc Nephrol. 2004;15(7):1731–1738.
  47. Ulianich L, et al. ER stress is associated with dedif-












































enmann M.  Tubular  toxicity  in  sirolimus-  and 
cyclosporine-based transplant immunosuppression 
strategies: an ancillary study from a randomized con-






















































393 biopsies. Am J Kidney Dis. 2002;39(4):713–720.
Downloaded from http://www.jci.org on November 8, 2017.   https://doi.org/10.1172/JCI44771
